Q2
AQST — Q2 2026 Financial Report Analysis
Aquestive revenue rose 38% to $13.8M on higher Suboxone volumes and the operating loss narrowed to $8.2M, but an $11.7M charge for refinancing its 13.5% notes widened the net loss to $22.9M ($0.18/share) ahead of a planned Q3 Anaphylm resubmission.